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Abstract
Background: Pancreatic cancer has highly aggressive features, such as local recurrence that leads to significantly
high morbidity and mortality and recurrence after successful tumour resection. Intraoperative radiation therapy
(IORT), which delivers targeted radiation to a tumour bed, is known to reduce local recurrence by directly killing
tumour cells and modifying the tumour microenvironment.
Methods: Among 30 patients diagnosed with pancreatic cancer, 17 patients received IORT immediately after
surgical resection. We investigated changes in the immune response induced by IORT by analysing the peritoneal
fluid (PF) and blood of patients with and without IORT treatment after pancreatic cancer surgery. Further, we
treated three pancreatic cell lines with PF to observe proliferation and activity changes.
Results: Levels of cytokines involved in the PI3K/SMAD pathway were increased in the PF of IORT-treated patients.
Moreover, IORT-treated PF inhibited the growth, migration, and invasiveness of pancreatic cancer cells. Changes in
lymphocyte populations in the blood of IORT-treated patients indicated an increased immune response.
Conclusions: Based on the characterisation and quantification of immune cells in the blood and cytokine levels in
the PF, we conclude that IORT induced an anti-tumour effect by activating the immune response, which may
prevent pancreatic cancer recurrence.
Clinical trial registration: NCT03273374.
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Background
Pancreatic cancer is reportedly one of the most aggres-
sive cancers and the fourth leading cause of cancer-
related deaths [1]. Despite improvements in treatment,
the 5-year survival of patients remains < 5%. Moreover,
although curative resection is the only choice for pancre-
atic cancer, it has been insufficient in improving long-
term survival [2]. Alternatively, radiation therapy could
provide a treatment option to increase the survival rate
of patients with pancreatic cancer by inducing the im-
mune activity of cytokines.
The conventional external beam radiation therapy
(EBRT) of pancreatic cancer is extremely challenging. Its
effectiveness is limited because adequate radiation can-
not be provided owing to the low tolerance of adjacent
organs [3, 4]. Recent advanced radiotherapy techniques,
such as intensity-modulated radiotherapy (IMRT),
image-guided radiotherapy (IGRT), magnetic resonance
(MR)-guided RT, and particle therapy have improved
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outcomes in pancreatic cancer patients [5–7]. However,
these treatments are limited to patients with unresect-
able or borderline resectable pancreatic cancer, and their
clinical use as adjuvant to conventional treatments has
not yet been established. Intraoperative radiation therapy
(IORT) using a portable instrument delivers a single
fraction of high-dose radiation during surgery [8, 9] that
effectively focuses intense radiation to a desired site and
simultaneously reduces toxicity to normal tissues [4, 10].
A high dose of radiation triggers immunogenic cell
death and stimulates anti-cancer immune response [11,
12]. Irradiation activates IFN-dependent immunity via
the formation of DAMP molecules and upregulates the
expression of pro-inflammatory cytokine genes by regu-
lating NF-kB [13]. These cytokine cascades are radiation
dose-dependent and have shared characteristics. A num-
ber of studies have described the effects of various com-
plex components in the inflammatory microenvironment
that increase the therapeutic effect by controlling the dy-
namic anti-cancer immune response [14, 15]. Therefore,
the anti-tumour immune response could be an import-
ant mechanism responsible for modulating the immuno-
suppressive microenvironment.
The only prospective randomised control trial to in-
vestigate the effectiveness of IORT to date was per-
formed in Japan, although an increased survival was not
confirmed [16]. However, other studies have shown that
IORT significantly improves local control and overall
survival in patients with pancreatic cancer by reducing
post-operative complications and mortality [17, 18].
High-dose irradiation directly induces DNA damage in
irradiated cells and changes the tumour microenviron-
ment. According to Kulcenty et al., IORT not only alters
the composition of anti-tumour-related cytokines in the
surgical wound fluid, but also affects the tumorigenic
properties of breast cancer [19]. Thus, research studies
are currently underway to decipher the effects of IORT
on the tumour microenvironment, but little is known
about pancreatic cancer.
The aim of this study was to investigate changes in the
tumour microenvironment after IORT and its effects on
pancreatic cancer. We also examined changes in pancre-
atic cancer cell proliferation and invasiveness using peri-
toneal fluid (PF) samples from IORT-treated patients
with pancreatic cancer. This study improves our under-
standing of how IORT-induced changes in the tumour
microenvironment alter the immune response and in-




This single-institution prospective phase II study was ap-
proved by the institutional review board (3–2015-0102)
and written informed consent was obtained from each
patient. Thirty patients diagnosed with pancreatic cancer
at the Gangnam Severance Hospital from 2018 to 2019
underwent pancreatic resection (Supplementary Table
S1, Supplementary Table S2). The eligibility criteria were
as follows: 1) age 20 years or older; 2) histologically or
clinically confirmed pancreatic carcinoma; 3) Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus scores of 0–2; 4) resectable disease defined as fol-
lows: absence of distant metastases; absence of direct
involvement of the inferior vena cava or aorta; and clear
fat planes around the celiac axis, hepatic artery, and su-
perior mesenteric artery; 5) stage I–III disease as per the
7th edition of the American Joint Committee on Cancer
(AJCC); 6) good bone marrow function (haemoglobin
level > 10 g/dL, absolute neutrophil count > 1500/mm3,
and platelet count > 100,000/mm3); and 7) adequate
renal function (serum creatinine level < 1.4 mg/dL and
blood urea nitrogen level < 20mg/dL). Patients who 1)
had previously received RT to the abdominal area; 2)
had a tumour bed that could not be adequately covered
by the IORT field as defined by the radiation oncologist;
3) had received neoadjuvant chemotherapy; 4) had syn-
chronous distant metastasis; 5) were pregnant or nurs-
ing; or 6) had any condition rendering them unsuitable
for IORT (at the discretion of the physicians) were ex-
cluded from this study.
Treatment scheme
A total of 17 patients were treated with IORT (irradiated
with a single dose of 10 Gy at a depth of 5 mm into the
tumour bed) immediately after surgical resection, as pre-
viously described [20]. Patients were subjected to
curative resection, either pylorus-preserving pancreato-
duodenectomy (PPPD), distal pancreatectomy, or total
pancreatectomy. A mobile 50-kV X-ray source (Intra-
beam, Carl Zeiss, Germany) was used for IORT. The tar-
get volume included the tumour bed, the celiac and
superior mesenteric arteries, the mesenteric root, and
the portal vein; any areas deemed at risk by the surgeon
and radiation oncologist were also included. A spherical
applicator with a diameter of 3.5 cm was used. An add-
itional shielding device was attached to the spherical ap-
plicator, leaving only the bottom surface unshielded
from which the X-ray beam was delivered to the tumour
bed. The target volume was irradiated with a single dose
of 10 Gy, prescribed at a 5-mm depth into the tumour
bed.
Peritoneal fluid collection
Patients were divided into the group that received IORT
(IORT PF, n = 17) and the group that did not receive
IORT (no IORT, n = 13). PF was collected from the
usual surgical drain 24 h after the surgery. Sterile filtered
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PF samples were centrifuged at 2100 rpm for 15min and
then stored at − 80 °C.
Blood sample collection and isolation of peripheral blood
mononuclear cells
Blood was collected three times from patients (post-op-
eration day (POD) 1, 7, and 14) using vacutainer EDTA
tubes (BD Biosciences, San Jose, CA, USA). Whole blood
was diluted with Dulbecco’s phosphate-buffered saline
(DPBS), gently layered over an equal volume of Ficoll-
Paque solution (GE Healthcare, Logan, UT, USA), and
centrifuged at 400 g for 30–40min. Peripheral blood
mononuclear cells (PBMCs) were collected from the sec-
ond layer, and any remaining platelets were gently
washed off using DPBS. Cells were resuspended in freez-
ing medium containing 10% DMSO and 90% foetal bo-
vine serum (FBS; Biowest, Riverside, MO, USA) and
stored at − 80 °C.
Cell culture
Mia PaCa-2, Panc1, and Aspc1 cells were obtained from
American Type Culture Collection (Manassas, VA,
USA). Cells were cultured in DMEM or RPMI medium
(Biowest) supplemented with 10% FBS (Biowest) and 1%
antibiotic–anti-mycotic reagent (Gibco, Waltham, MA,
USA). Cells were incubated at 37 °C in a humidified at-
mosphere under 5% CO2.
Cytokine array
PF samples were assayed using the Human Cytokine
Antibody Array kit (Abcam, Cambridge, UK) according
to the manufacturer’s instructions. Briefly, each sample
was incubated for 24 h at 4 °C and then paired with bio-
tinylated detector antibodies and horseradish peroxidase
(HRP)-conjugated streptavidin. Each cytokine was ana-
lysed using chemiluminescence and levels were quanti-
fied using ImageJ software (National Institutes of Health,
Bethesda, MD, USA).
Flow cytometry
Isolated PBMCs were stained with the following
fluorochrome-conjugated monoclonal antibodies: anti-
human APC-CD4 (eBioscience, San Diego, CA, USA),
APC-cy7 CD8 (BD Biosciences, San Jose, CA, USA), PE-
cy5 CD25 (Biolegend, San Diego, CA, USA), PE-Cy7
Foxp3 (eBioscience), BV421 CD56 (BD Biosciences, San
Jose, CA, USA), and APC-CD19 (Biolegend). Live cells
were classified using propidium iodide (BD Biosciences,
San Jose, CA, USA) staining. Lymphocytes were further
subtyped by their staining properties as T cells (CD3+),
Th cells (CD3 + CD4+), Tc cells (CD3 + CD8+), NK cells
(CD3-CD56+), or Treg cells (CD4 + CD25 + FOXP3+).
Treg cells were fixed and underwent permeabilisation
using the Fix & Perm Buffer (eBioscience), and stained
cells were analysed using BD FACSCanto II Cell
Analyzer (BD Biosciences, San Jose, CA, USA). FlowJo
software (BD Biosciences, San Jose, CA, USA) was used
for compensation and data analysis.
Proliferation assays
For the 2D proliferation assay, 1.5–3 × 103 cells per well
were seeded into a 96-well cell culture plate. Cells were
allowed to grow in serum-free medium supplemented
with 5% FBS or PF. After incubation for 4 days, reduced
medium with 10% WST-1 reagent (EZ-cytox, Dogen,
Korea) was placed into the wells after aspiration of the
growth medium. The absorbance of each well was mea-
sured at 450 nm using a VersaMax microplate reader
(Molecular Devices, San Jose, CA, USA).
For the colony formation assay, 100–500 cells/well
were seeded into six-well culture plates containing re-
duced serum medium supplemented with 5% PF and an-
tibiotics. The medium was replaced every 3 days until
colonies formed. The rate of colony formation was dif-
ferent for each cell, usually taking 7–14 days. Cells were
fixed in cold 100% methanol for 30 min, stained using
2.5% crystal violet, and then washed several times with
phosphate-buffered saline (PBS). Colony formation was
calculated manually and digitally using ImageJ software,
where colony area versus total area was calculated based
on staining intensity.
Migration and invasion assays
For the invasion assay, the 8 μm pore size Transwell sys-
tem (Corning, Midland, MI, USA) was coated with
Matrigel (1:50, Corning) at 37 °C for 1 h. Then, 2 × 104
cells were seeded on the apical side of the Transwell
chamber (24-well insert) in serum-free media. DMEM
with 7% PF and 1% antibiotic–anti-mycotic agent was
added to the basal compartment. The cells were allowed
to invade for at 37 °C 24 h. The cells that remained in
the top chamber were gently scraped off using wet cot-
ton swabs. The cells that invaded the basal side were
fixed in methanol for 10 min, stained with 0.2% crystal
violet, and then washed multiple times with distilled
water. The invasion assays were performed in triplicate.
For the scratch wound migration assay, 2 × 104 cells
were seeded into a 96-well plate (Image lock, IncuCyte™;
Essen Bioscience, Ann Arbor, MI, USA), and wound
scratches were made using a wound maker tool (Essen
Bioscience) 18 h after plating. The media in each well
was supplemented with 5% PF and 1% antibiotic–anti-
mycotic agent, and FBS was used as positive control. Im-
ages of the migrated cells were captured automatically
every 4 h, and the relative wound density was analysed
using IncuCyte™ Chemotaxis Cell Migration Software
(Essen Bioscience).
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Western blotting
After the indicated treatment, cells were harvested and
washed with ice-cold PBS and lysed using RIPA lysis
buffer. Proteins (30 μg sample) were separated using
SDS-PAGE and transferred onto nitrocellulose mem-
branes, blocked in 5% skim milk, and incubated with the
following primary antibodies (1:1000): Anti-phospho-
smad2, phospho-smad3, smad2, and smad3 (Cell Signal-
ing Technology, Danvers, MA, USA), anti-Snail+slug
(Abcam), anti-vimentin (Cell Signaling Technology), N-
cadherin (BD Biosciences, San Jose, CA, USA), E-
cadherin (BD Biosciences, San Jose, CA, USA), and γ-
tubulin (Sigma-Aldrich, St. Louis, MO, USA). The mem-
branes were then washed thrice with Tris-buffered saline
and Tween 20 (TBST), followed by incubation with
HRP-conjugated secondary antibody (1:7000, Cell Sig-
naling Technology) in TBST with 3% skim milk. Bound
antibody was probed using ECL solution.(Bio-Rad, USA)
Chemiluminescent signals were captured using X-ray
films. All experiments were performed in triplicate.
RNA isolation and qPCR
After the indicated treatment, cells were collected, and
their RNA was isolated using TRIZOL Reagent® (Sigma-
Aldrich) according to the manufacturer’s instructions.
Then, 0.2 μg total isolate RNA was analysed via reverse
transcriptase PCR using the One-Step RT-PCR Kit (iN-
tRON Biotechnology, Seongnam-Si, Korea). First-strand
cDNA synthesis was performed with 1 μg RNA as a tem-
plate using the RT-qPCR cDNA Synthesis Kit (iNtRON
Biotechnology), according to the manufacturer’s instruc-
tions. RT-qPCR was performed using the SYBR qPCR
reaction mix (Applied Biosystems, Foster City, CA,
USA). The primer sequences used in this study are listed
in Table 1. Relative mRNA expression level was calcu-
lated using the 2−ΔΔCT method, using GAPDH as the
reference gene.
Statistical methods
Statistical analysis was performed using GraphPad Prism
version 8.01 software (GraphPad Software, La Jolla, CA,
USA). Unpaired t-test was performed for statistical ana-
lysis of cytokine array, cell proliferation, western blot-
ting, and qPCR data. Wound healing assay and PBMC
phenotyping data were analysed by two-way ANOVA.
Differences were considered statistically significant at *
p < 0.05, ** p ≤ 0.01.
Results
Peritoneal fluid from IORT-treated patients displayed
cytokine composition changes
We investigated cytokine changes induced by IORT in
the PF of 30 patients with pancreatic cancer (Fig. 1A).
Our results revealed that the relative signal intensity of
19 cytokines were higher in the IORT PF group than in
the no IORT group, whereas levels of 17 cytokines were
decreased (Fig. 1B, Supplementary Table S3). Among
them, the levels of IFN-γ (p = 0.0357), IL-15 (p = 0.0172),
platelet-derived growth factor (PDGF)-BB (p = 0.0042),
and TGF-β (p = 0.0174) differed significantly with re-
spect to the presence or absence of IORT (Fig. 1C). We
further investigated whether these cytokine profile differ-
ences were related to the activation of intracellular path-
ways in pancreatic cancer cells (Fig. 1D). Pancreatic
cancer cells incubated with IORT-treated PF for 4 h dis-
played activated cytokine-related signalling pathways
(PI3K-Akt, Smad2/3) compared with cells incubated
with no IORT-treated PF (Fig. 1E). Hence, IORT altered
the cytokines secreted into the peritoneal cavity after
surgery.
IORT-treated PF suppressed pancreatic cancer cell growth
Next, we performed WST-1-based proliferation assays
on Mia PaCa-2, Panc1, and Aspc1 cells to confirm the
influence of IORT-treated PF on pancreatic cancer cell
proliferation (Fig. 2A). The proliferation of pancreatic
cancer cells stimulated by no IORT-treated PF was com-
parable to that of cells cultured in complete media (with
FBS). However, pancreatic cancer cells in the IORT PF
group demonstrated significantly reduced proliferation
compared with those in the no IORT PF group. This dif-
ference was most pronounced in the Panc1 cells. Add-
itionally, a similar pattern of IORT influence was
displayed in the colony formation assay (Fig. 2B). PF
exerted a stimulating effect on pancreatic cancer cell
proliferation, which was inhibited in the IORT PF group.
IORT-treated PF decreased invasiveness and wound
healing activity of pancreatic cancer cells
Next, we analysed the effect of IORT-treated PF on the
invasive capability of pancreatic cancer cells through a
3D Matrigel-coated Transwell-based assay using five
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Fig. 1 Intraoperative radiation therapy (IORT) leads to differential cytokine profile of the peritoneal fluid (PF) and affects PI3K/Smad signalling in
pancreatic cancer cells. A Cytokine membrane array images. Each spot represents a cytokine hybridised in patient PF. B Heat map visualisation
comparing cytokine array results. C. Cytokines significantly upregulated in the PF of IORT-treated patients (IORT n = 15, no IORT n = 11). D.
Schematic overview of signalling pathways (PI3K-Akt, Smad2/3) in cancer cells associated with cytokines TGF-β, IFN-γ, and PDGF-BB. E. Western
blot analysis of signalling-related protein xpression in Panc1 cells incubated with PF for 4 h. IORT: P3, P54, and P56; no IORT: P31, P33, and P42
(unpaired t-test; *p < 0.05 and **p≤ 0.01)
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randomly selected PF samples from each group. Incuba-
tion with IORT-treated PF reduced the invasiveness of
all three pancreatic cancer cell lines (Fig. 3A). Assessing
the migratory ability of cells incubated with PF over time
(Fig. 3B) revealed that cells in the IORT PF group had a
slower wound closure rate than those in the no IORT
group.
IORT changed the expression of epithelial-mesenchymal
transition (EMT) markers in pancreatic cancer cells
We treated Mia PaCa-2, Panc1, and Aspc1 cells with the
same 7% PF used in the invasion assay. Comparing the
average expression levels of EMT-related genes in PF-
treated cells indicated that the expression of epithelial
marker E-cadherin was increased, but that of mesenchy-
mal markers vimentin, snail, and N-cadherin was de-
creased in the IORT PF-treated cells (Fig. 4A).
According to the western blot results, expression levels
of the mesenchymal markers were decreased in the
IORT PF group (Fig. 4B). These data implied that treat-
ment with IORT-treated PF regulated the expression of
EMT markers in pancreatic cancer cells, ultimately inhi-
biting cell invasiveness and migration activity.
Changes in lymphocyte phenotypes indicated increased
immune response after IORT
Blood samples were collected from each patient group
on POD 1, 7, and 14, after which flow cytometry was
performed on the isolated PBMCs (Fig. 5A). The indi-
cated immune cell population values on POD 7 and 14
were normalised to those on POD 1 (Fig. 5B). The total
T cell population displayed a higher rate of increase dur-
ing the 14-day post-operative period in the IORT PF
group than in the no IORT group. Specifically, cytotoxic
and helper T cell populations demonstrated significantly
higher increasing rates in the IORT PF group than in
the no IORT group. (Tc cell p = 0.0076, Th cell p =
0.0456) In the case of the NK cell population, a signifi-
cantly higher increasing rate was observed during the
first 7 days post-surgery in the IORT PF group than in
the no IORT group. (p = 0.0216) Moreover, Treg cells
maintained a reduced ratio throughout the 14-day post-
operative period in the IORT PF group compared with
that in the no IORT group. (p = 0.0242) These results in-
dicated that IORT exerts a systemic effect on the micro-
environment around the surgical site through the
immune response.
Fig. 2 Peritoneal fluid (PF) stimulates cancer cell proliferation. A. Mia PaCa-2, Panc1, and Aspc1 cell lines were incubated for 4 days in the
presence of PF at the indicated concentrations. As a positive control, foetal bovine serum (FBS) was used at the same concentration as PF.
Incubated cells were treated with WST-1 solution, and absorbance was detected at 450 nm. B. Cells were incubated in the presence of PF until
the colonies were formed. Colonies were stained with crystal violet, and the percentage of colony areas were calculated using ImageJ software.
Columns correspond to the mean of three independent experiments; bars indicate SD. Statistical analyses were performed using the
unpaired t-test
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Fig. 3 Intraoperative radiation therapy (IORT)-treated peritoneal fluid (PF) decreased the invasiveness and wound healing ability of pancreatic
cancer cells. A. Pancreatic cancer cell lines were tested for their invasiveness using Matrigel-coated Transwell chemotaxis assays. Random PF
samples (7% in DMEM) were loaded in the bottom well of the transwell plate for pancreatic cancer cell treatment. Invaded cells were stained and
analysed after 24 h. B. Pancreatic cancer cells cultured in 96-well plates were scratched using a wound maker and treated with PF for observing
cell migration every 12 h
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Discussion
Cytokines and growth factors secreted by tumour cells
and surrounding cells are affected by radiation therapy
and by invasive procedures, such as surgery [21, 22].
IFN, TGF-β, IL-1β, IL-6, IL-7, and granulocyte-
macrophage colony-stimulating factor (GMCF) are
known to regulate pro- and anti-immune responses [23].
In the current study, we identified cytokines secreted at
elevated levels in the PF of IORT-treated patients with
pancreatic cancer compared with those in the PF of pa-
tients who underwent surgical resection alone. Specific-
ally, IFN-γ, TGF-β, IL-15, and PDGF-BB displayed
significant differences between groups. TGF-β is a cyto-
kine with dual effects on cancer because it exerts inhibi-
tory cancer activity in the early stages of carcinogenesis
but promotes cancer growth in the later stages [24, 25].
In particular, increased TGF-β secretion induces radio-
resistance and is known to be a major modulator of the
anti-cancer immune response during radiation therapy
[26]. In our study, the TGF-β level was significantly in-
creased in the IORT PF group, likely owing to radiation
response [27]. Among the relatively highly expressed cy-
tokines, IFN-γ is involved in mediating the anti-tumour
effects of radiation therapy [28]. It is produced by related
CD8+ T and NK cells through immune stimulation or
inflammatory reactions, and subsequently affects the ac-
tivity of these cells after radiation exposure [29]. Con-
curring with the results of previous studies, our data
confirmed that post-operative IORT maintained a rela-
tively high proportion of CD8+ T and NK cells in the
blood and increased the IFN-γ level, which would lead
to anti-cancer immune responses.
PDGF-BB, another relatively highly expressed cytokine,
improves cell viability and induces cell proliferation and
migration of several types of tumours. In accordance
with our study results, PDGF-BB expression reportedly
increases with TGF-β expression throughout the radi-
ation process [24]. PI3K-Akt signalling induced by
Fig. 4 Changes in EMT marker expression in cancer cells following treatment with peritoneal fluid (PF) collected after intraoperative radiation
therapy (IORT). A. qPCR was used to measure the expression levels of EMT-related genes encoding mesenchymal markers (vimentin, snail, and N-
cadherin) and epithelial markers (E-cadherin). B. Western blotting analysis of the expression of indicated EMT markers. RNA and protein were
extracted from cells after 4 days of treatment. Used PF were from IORT (P1, P43, P56, and P64) and no IORT (P26, P42, P45, and P62). The results
were statistically analysed using the unpaired t-test, and significance was marked at *: p < 0.05 and **: p < 0.01 using three independent
biological replicates
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PDGF-BB is known to contribute to the migratory regu-
lation of cancer progression [25]. Similar to the results
of previous studies, PDGF-BB expression in the IORT
PF group was elevated, and we confirmed that it affected
PI3K-Akt signalling during PF treatment of pancreatic
cancer cells. IL-15 is generally known to activate the in-
nate immune system by inducing the differentiation and
proliferation of NK cells [30]. In the present study, we
confirmed its effect on PI3K-Akt signalling when pan-
creatic cancer cells were treated with PF, which con-
curred with similar results reported in a previous study
[31]. Nevertheless, to confirm the effect of IORT on im-
mune cells, further comparative response studies are
needed. According to a previous study investigating
IORT in breast cancer, levels of PF, IL-4, and IL-5,
which are known to be increased by radiation, were ele-
vated, whereas those of IL-6, RANTES, and HGF, which
are known to control tumour cell growth and motility,
were decreased in the surgical wound fluid of breast can-
cer patients [32]. In another breast cancer study, levels
of IL-7, IL-8, IL-13, macrophage migration inhibitory
factor (MIF), and TNF-β were increased, whereas those
Fig. 5 Changes in immune cell composition of PBMCs during the follow-up period of IORT-treated patients with pancreatic cancer. A.
Representative flow cytometry plots illustrating the gating strategy used in the analysis of lymphocytes in the blood (left: CD3-CD56+ NK cell;
middle: CD3 + CD4+ helper T cell and CD3 + CD8+ cytotoxic T cell; right: CD3-CD25 + FOXP3+ Treg cell). B. Rate of change in the indicated
immune cells according to the blood collection time (baseline = post-operation day (POD) 1, normalised to each POD 1 value). C. Scheme of
immune response by IORT treatment after pancreatic cancer surgery
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of CTACK, G-CSF, HGF, IL-1β, and TNF-α were de-
creased after IORT exposure [19]. Although our data did
not demonstrate significant differences in cytokine
levels, except for IL-8 and TNF-α, a similar trend in the
data suggests that immunological effects are induced by
IORT in pancreatic cancer. The differences displayed by
cytokines in our study compared with those in previous
studies highlight that pancreatic cancer has higher het-
erogeneity than other types of cancer, which may lead to
different tendencies that could be reflected in the pan-
creatic cancer tumour [33].
The cytokines and chemokines present in PF affect the
EMT process of cancer cells, and ultimately, invasion
and metastasis. TGF-β1 reportedly induces the Smad4-
dependent EMT transition in Panc1 cells, increasing the
E-cadherin level while decreasing the N-cadherin and
vimentin levels [34]. CXCR4 also activates the Wnt and
Hedgehog signalling pathways to express the EMT
phenotype and promotes CXCL12-mediated pancreatic
cancer cell invasion and metastasis [35]. Belletti et al.
first reported the stimulating role of post-operative fluid
on the proliferation and migration of breast cancer cells
[32]. In particular, Kulcenty et al. observed expression of
the EMT phenotype and induction of cell migration
when breast cancer cells were treated with post-
operative fluid, which was abrogated by IORT treatment
[36]. In the present study, proliferation, invasion, and
motility of all three pancreatic cell lines were stimulated
by PF, the effects of which were suppressed in cells stim-
ulated with IORT-treated PF. Epithelial and mesenchy-
mal markers in pancreatic cancer cells were used to
confirm inhibition of the EMT process, revealing the
same pattern as the functional assay. These results are
consistent with the above-mentioned studies, indicating
that IORT-induced changes in the tumour microenvir-
onment are responsible for suppression of the prolifera-
tion, invasiveness, and migratory ability of pancreatic
cancer cells.
Analysing blood samples after surgery, we confirmed
that the ratio of anti-tumour immune cells on POD 1
was decreased in most patients compared with that be-
fore surgery but was gradually recovered to pre-
operative levels over time (data not shown). Hence, we
compared the proportion of immune cells that changed
over time based on the levels measured on POD 1. Cyto-
toxic T cell and NK cell populations demonstrated a
tendency towards higher increasing rates after surgery
among patients who received IORT. Conversely, the
abundance of Treg cells, which are immune suppressive
cells, remained low in patients who received IORT. Ir-
radiation of the cavity from which the tumour is re-
moved causes apoptosis in the few remaining tumour
cells and lymphocytes, and secretion of DAMP, tumour
antigens, and cytokines, consequently establishing an
environment that attracts immune cells, called the “by-
stander effect” [37, 38]. Our results support the forma-
tion of an inflammatory microenvironment induced by
high-dose irradiation that can trigger an anti-tumour im-
mune response in pancreatic cancer through the by-
stander effect. Pancreatic cancer is a representative “cold
tumour”; the implementation of IORT may contribute to
a positive feedback loop that continuously activates
immune-related cells, thereby forming an immune envir-
onment that would improve local control of pancreatic
cancer.
Drainage insertion after pancreatic cancer surgery is
controversial; nevertheless, many surgeons perform
draining because of complications caused by pancreatic
fistulas [39]. Drainage fluid collected from the abdominal
cavity of patients with pancreatic cancer has been used
as a diagnostic indicator of pancreatic leaks or ascites,
unlike wound fluid from breast cancer surgery [40, 41].
Various cancers, including pancreatic cancer, are known
to protect malignant cells and accumulate fluid (malig-
nant effusion) through the secretion of cytokines, growth
factors, or peptides [42]. Several studies have investi-
gated the tumour microenvironment through PF analysis
for other cancer types, but little research has been con-
ducted on PF in pancreatic cancer to date [43, 44]. The
present study improves our understanding of the pan-
creatic cancer tumour microenvironment through com-
ponent analysis and related signalling pathways in the
PF, with respect to IORT after pancreatic cancer surgery.
However, further evaluation is needed to compare serum
cytokine levels and more accurately correlate immune
responses altered by IORT.
The local recurrence rate of pancreatic cancer is high
even after radical surgery and adjuvant chemotherapy
[2]. In our study, among patients who underwent sur-
gery, local recurrence occurred in 31.3% (5/16) of pa-
tients who received IORT and 50% (5/10) of those who
did not receive IORT (Supplementary Table S4). In
addition, when the 1-year disease-free survival rate was
analysed based on the 2-year follow-up data, it was con-
firmed that the IORT group had a higher rate (Supple-
mentary Fig. S1). Although they did not reach statistical
significance, these findings support disease-free survival
and local recurrence benefits via IORT of pancreatic
cancer.
This study has several limitations that should be ac-
knowledged when interpreting the results. First, this was
a prospective study with nonrandomised patients be-
cause it was classified according to patient consent. Sec-
ond, because the PF used in this study was derived from
the entire abdominal cavity, it is possible that the other
factors such as stress and inflammation from surgery, in
addition to IORT, may have influenced the results.
Third, only the indirect immune effects by IORT could
Lee et al. BMC Cancer         (2021) 21:1097 Page 10 of 12
be confirmed through the ratio analysis of PBMC cells
using blood.
Conclusion
This is the first study to employ blood and PF to con-
firm the effect of IORT on pancreatic cancer cells and
the anti-cancer immune response after surgical resec-
tion. We identified differentially expressed cytokines in
PF and compared the effect of IORT administration on
the proliferation and activity of pancreatic cancer cells
stimulated by PF. We also confirmed the anti-cancer
immune response induced by IORT through compari-
son of immune cell populations during the post-
operative period. Through this study, we can conclude
that various cytokines at the surgical site induce micro-
environment changes after IORT, which inhibit the
proliferation of remaining cancer cells and recurrence
(Fig. 5C). Therefore, IORT induces an anti-cancer im-
mune response in patients with pancreatic cancer, ul-
timately aiding local control and prevention of
pancreatic cancer recurrence.
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